This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hayes, V. M. Articles by Giles, G. G. Search for Related Content PubMed PubMed Citation Articles by Hayes, V. M. Articles by Giles, G. G.

Genetic Variants in the Vitamin D Receptor Gene and Prostate Cancer Risk

¹ Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst, Sydney, New South Wales; ² Cancer Epidemiology Centre, The Cancer Council Victoria, Carlton; and ³ Department of Pathology and ⁴ Centre for Genetic Epidemiology, University of Melbourne, Parkville, Melbourne, Victoria, Australia

Requests for reprints: Vanessa M. Hayes, Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, 384 Victoria Street, Darlinghurst, New South Wales 2010, Australia. Phone: 61-2-9295-8345; Fax: 61-2-9295-8321. E-mail: v.hayes{at}garvan.org.au

Vitamin D receptor (VDR), a member of the steroid/thyroid hormone nuclear receptor family, is bound by the steroid hormone 1,25-dihydroxyvitamin D₃, which is thought to play a role in the etiology and progression of prostate cancer. Polymorphisms in the VDR gene have been associated with prostate cancer risk, although findings are inconclusive. The purpose of this study was to determine if VDR polymorphisms were associated with prostate cancer risk using a large, Australian population–based study of 812 cases and 713 controls frequency-matched by age. As the 3' region polymorphisms are in strong linkage disequilibrium, for joint effects, we only evaluated the common g.60890G > A polymorphism with the unlinked g.27823C > T (5' region) polymorphism. Allele frequencies were similar in cases and controls (g.27823C > T, 36% versus 36%; g.60890 G>A, 41% versus 43%). No genotypes were individually associated with prostate cancer risk (all P > 0.3). All nine possible genotype combinations were evident, and although the g.27823CT/g.60890GA combination was nominally more prevalent in controls (24%) than in cases (19%, P = 0.03), there was no difference in the combined genotype distribution between cases and controls (P = 0.2). The associations of risk with genotype were between 0.91 and 1.03, all with 95% confidence intervals within 0.81 to 1.15. In conclusion, VDR polymorphisms either alone or in combination do not seem to contribute appreciably to prostate cancer risk.

This article has been cited by other articles:

				G. Severi, V. M. Hayes, E. J.D. Padilla, D. R. English, M. C. Southey, R. L. Sutherland, J. L. Hopper, and G. G. Giles The Common Variant rs1447295 on Chromosome 8q24 and Prostate Cancer Risk: Results from an Australian Population-Based Case-Control Study Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 610 - 612. [Abstract] [Full Text] [PDF]

				M. S. Cicek, X. Liu, F. R. Schumacher, G. Casey, and J. S. Witte Vitamin D Receptor Genotypes/Haplotypes and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2549 - 2552. [Abstract] [Full Text] [PDF]

				G. Severi, V. M. Hayes, P. Neufing, E. J.D. Padilla, W. D. Tilley, S. A. Eggleton, H. A. Morris, D. R. English, M. C. Southey, J. L. Hopper, et al. Variants in the Prostate-Specific Antigen (PSA) Gene and Prostate Cancer Risk, Survival, and Circulating PSA. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1142 - 1147. [Abstract] [Full Text] [PDF]